Symbols / ACRS $3.80 -9.52% Aclaris Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
ACRS Chart
About

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 460.13M
Enterprise Value 417.86M Income -64.92M Sales 7.83M
Book/sh 0.85 Cash/sh 0.75 Dividend Yield —
Payout 0.00% Employees 69 IPO —
P/E — Forward P/E -5.07 PEG —
P/S 58.80 P/B 4.44 P/C —
EV/EBITDA -5.64 EV/Sales 53.39 Quick Ratio 3.36
Current Ratio 3.36 Debt/Eq 2.05 LT Debt/Eq —
EPS (ttm) -0.53 EPS next Y -0.75 EPS Growth —
Revenue Growth -85.90% Earnings 2026-05-07 ROA -24.32%
ROE -50.20% ROIC — Gross Margin 0.00%
Oper. Margin -17.25% Profit Margin 0.00% Shs Outstand 121.09M
Shs Float 89.69M Short Float 4.54% Short Ratio 1.84
Short Interest — 52W High 4.89 52W Low 1.05
Beta 0.68 Avg Volume 2.41M Volume 2.01M
Target Price $8.29 Recom Strong_buy Prev Close $4.20
Price $3.80 Change -9.52%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.29
Mean price target
2. Current target
$3.80
Latest analyst target
3. DCF / Fair value
$-4.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.80
Low
$3.00
High
$16.00
Mean
$8.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 reit Wedbush Outperform → Outperform $8
2026-03-19 reit HC Wainwright & Co. Buy → Buy $16
2026-01-28 reit HC Wainwright & Co. Buy → Buy $16
2026-01-21 reit HC Wainwright & Co. Buy → Buy $16
2025-10-20 reit HC Wainwright & Co. Buy → Buy $16
2025-06-25 reit HC Wainwright & Co. Buy → Buy $16
2025-05-28 init Wedbush — → Outperform $8
2025-05-14 main HC Wainwright & Co. Buy → Buy $16
2025-05-09 main Scotiabank Sector Outperform → Sector Outperform $9
2025-03-18 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-07 init Scotiabank — → Sector Outperform $15
2024-12-23 up HC Wainwright & Co. Neutral → Buy $20
2024-11-19 up Leerink Partners Market Perform → Outperform $7
2024-11-19 up Jefferies Hold → Buy $7
2024-11-19 up BTIG Neutral → Buy $8
2024-11-18 up Piper Sandler Neutral → Overweight $13
2024-09-17 reit HC Wainwright & Co. — → Neutral —
2024-08-19 reit HC Wainwright & Co. — → Neutral —
2024-07-22 reit HC Wainwright & Co. — → Neutral —
2024-01-22 down HC Wainwright & Co. Buy → Neutral —
News
RSS: Latest ACRS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-27 BALTHASER KEVIN J Chief Financial Officer — 2,375 — —
2026-02-03 WALKER NEAL Chief Executive Officer — 63,475 — —
2026-02-03 LOEROP JAMES Officer — 20,875 — —
2026-02-03 BALTHASER KEVIN J Chief Financial Officer — 22,025 — —
2026-02-03 DAVIS HUGH M. President — 18,675 — —
2026-01-30 LOEROP JAMES Officer — 33,500 — —
2026-01-30 BALTHASER KEVIN J Chief Financial Officer — 14,750 — —
2026-01-02 WALKER NEAL Chief Executive Officer — 29,150 — —
2026-01-02 LOEROP JAMES Officer — 91,900 — —
2026-01-02 BALTHASER KEVIN J Chief Financial Officer — 94,450 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
7.83
-58.19%
18.72
-40.09%
31.25
+5.03%
29.75
Operating Revenue
7.83
-58.19%
18.72
-40.09%
31.25
+5.95%
29.50
Cost Of Revenue
7.28
-52.88%
15.46
-14.51%
18.08
+51.18%
11.96
Reconciled Cost Of Revenue
7.28
-52.88%
15.46
-14.51%
18.08
+51.18%
11.96
Gross Profit
0.54
-83.38%
3.26
-75.23%
13.17
-25.99%
17.79
Operating Expense
70.80
+31.42%
53.88
-58.39%
129.48
+25.78%
102.95
Research And Development
52.65
+56.75%
33.59
-65.86%
98.38
+26.44%
77.81
Selling General And Administration
21.97
-1.04%
22.20
-28.60%
31.10
+23.73%
25.13
General And Administrative Expense
21.97
-1.04%
22.20
-28.60%
31.10
+23.73%
25.13
Salaries And Wages
14.92
+9.95%
13.57
-33.16%
20.30
+25.54%
16.17
Other Gand A
7.05
-18.31%
8.63
-20.03%
10.80
+20.48%
8.96
Other Operating Expenses
-3.81
-99.32%
-1.91
—
—
Total Expenses
78.09
+12.62%
69.33
-53.01%
147.56
+28.42%
114.91
Operating Income
-70.26
-38.82%
-50.61
+56.49%
-116.31
-36.59%
-85.15
Total Operating Income As Reported
-76.38
+46.19%
-141.93
-45.79%
-97.36
-8.35%
-89.85
EBITDA
-69.81
-40.16%
-49.81
+56.86%
-115.45
-36.86%
-84.36
Normalized EBITDA
-67.51
-270.47%
39.60
+129.46%
-134.41
-68.73%
-79.66
Reconciled Depreciation
0.45
-43.74%
0.81
-6.49%
0.86
+8.28%
0.80
EBIT
-70.26
-38.82%
-50.61
+56.49%
-116.31
-36.59%
-85.15
Total Unusual Items
-2.30
+97.43%
-89.41
-571.62%
18.96
+503.34%
-4.70
Total Unusual Items Excluding Goodwill
-2.30
+97.43%
-89.41
-571.62%
18.96
+503.34%
-4.70
Special Income Charges
-2.30
+97.43%
-89.41
-571.62%
18.96
+503.34%
-4.70
Other Special Charges
—
86.91
+1210.98%
6.63
—
Impairment Of Capital Assets
—
—
6.63
0.00
Restructuring And Mergern Acquisition
2.30
-8.00%
2.50
+109.29%
-26.90
-672.34%
4.70
Write Off
—
0.00
-100.00%
1.31
0.00
Net Income
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Pretax Income
-64.92
+50.84%
-132.06
-48.64%
-88.85
-2.23%
-86.91
Net Non Operating Interest Income Expense
7.64
-3.97%
7.95
—
—
Net Interest Income
7.64
-3.97%
7.95
—
—
Interest Income Non Operating
7.64
-3.97%
7.95
—
—
Interest Income
7.64
-3.97%
7.95
—
—
Other Income Expense
-2.30
+97.43%
-89.41
-425.51%
27.47
+1665.91%
-1.75
Other Non Operating Income Expenses
—
7.95
-6.53%
8.51
+188.83%
2.95
Tax Provision
—
0.00
+100.00%
-0.37
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.08
0.00
Net Income Including Noncontrolling Interests
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Net Income From Continuing Operation Net Minority Interest
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Net Income From Continuing And Discontinued Operation
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Net Income Continuous Operations
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Net Income Discontinuous Operations
—
—
—
0.00
Normalized Income
-62.62
-46.80%
-42.66
+60.26%
-107.36
-30.60%
-82.21
Net Income Common Stockholders
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Diluted EPS
—
-1.71
-34.65%
-1.27
+4.51%
-1.33
Basic EPS
—
-1.71
-34.65%
-1.27
+4.51%
-1.33
Basic Average Shares
—
77.30
+10.73%
69.81
+7.05%
65.21
Diluted Average Shares
—
77.30
+10.73%
69.81
+7.05%
65.21
Diluted NI Availto Com Stockholders
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Line Item Trend 2023-12-31
Total Assets
197.41
Current Assets
128.86
Cash Cash Equivalents And Short Term Investments
119.11
Cash And Cash Equivalents
39.88
Other Short Term Investments
79.23
Receivables
0.30
Accounts Receivable
0.30
Prepaid Assets
—
Other Current Assets
9.45
Total Non Current Assets
68.55
Net PPE
1.62
Gross PPE
5.78
Accumulated Depreciation
-4.16
Properties
0.00
Machinery Furniture Equipment
1.81
Other Properties
3.15
Leases
0.82
Goodwill And Other Intangible Assets
0.27
Other Intangible Assets
0.27
Investments And Advances
62.77
Other Investments
—
Other Non Current Assets
4.16
Total Liabilities Net Minority Interest
40.23
Current Liabilities
30.95
Payables And Accrued Expenses
24.41
Payables
8.88
Accounts Payable
8.88
Current Accrued Expenses
15.54
Pensionand Other Post Retirement Benefit Plans Current
3.91
Current Debt And Capital Lease Obligation
0.43
Current Capital Lease Obligation
0.43
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
2.63
Total Non Current Liabilities Net Minority Interest
9.27
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Non Current Deferred Taxes Liabilities
0.00
Other Non Current Liabilities
9.27
Stockholders Equity
157.18
Common Stock Equity
157.18
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
70.89
Ordinary Shares Number
70.89
Treasury Shares Number
0.00
Additional Paid In Capital
928.08
Retained Earnings
-770.80
Gains Losses Not Affecting Retained Earnings
-0.11
Other Equity Adjustments
-0.11
Total Equity Gross Minority Interest
157.18
Total Capitalization
157.18
Working Capital
97.90
Invested Capital
157.18
Total Debt
0.43
Capital Lease Obligations
0.43
Net Tangible Assets
157.18
Tangible Book Value
157.18
Available For Sale Securities
62.77
Investmentin Financial Assets
62.77
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-47.11
-134.68%
-20.07
+74.37%
-78.33
-15.92%
-67.57
Cash Flow From Continuing Operating Activities
-47.11
-134.68%
-20.07
+74.37%
-78.33
-15.92%
-67.57
Net Income From Continuing Operations
-64.92
+50.84%
-132.06
-49.26%
-88.48
-1.81%
-86.91
Depreciation Amortization Depletion
0.45
-43.74%
0.81
-6.49%
0.86
+8.28%
0.80
Depreciation And Amortization
0.45
-43.74%
0.81
-6.49%
0.86
+8.28%
0.80
Other Non Cash Items
2.30
-97.43%
89.41
+541.05%
-20.27
-531.30%
4.70
Stock Based Compensation
12.38
+14.08%
10.86
-47.15%
20.54
+36.59%
15.04
Asset Impairment Charge
—
—
6.63
0.00
Deferred Tax
—
0.00
+100.00%
-0.37
0.00
Deferred Income Tax
—
0.00
+100.00%
-0.37
0.00
Operating Gains Losses
—
—
—
—
Change In Working Capital
2.67
-75.54%
10.92
+16.33%
9.39
+885.69%
-1.20
Change In Receivables
—
-0.02
-110.75%
0.19
+33.81%
0.14
Changes In Account Receivables
—
-0.02
-110.75%
0.19
+33.81%
0.14
Change In Prepaid Assets
6.14
+225.91%
-4.88
-270.72%
-1.31
+42.68%
-2.29
Change In Payables And Accrued Expense
0.35
+104.31%
-8.13
-177.30%
10.52
+995.63%
0.96
Change In Accrued Expense
-8.10
-105.40%
-3.94
-132.87%
11.99
+1925.51%
0.59
Change In Payable
8.45
+301.70%
-4.19
-184.32%
-1.47
-500.27%
0.37
Change In Account Payable
8.45
+301.70%
-4.19
-184.32%
-1.47
-500.27%
0.37
Change In Other Working Capital
-3.82
-115.95%
23.93
—
—
Investing Cash Flow
48.37
+169.32%
-69.77
-250.95%
46.22
+266.01%
12.63
Cash Flow From Continuing Investing Activities
48.37
+169.32%
-69.77
-250.95%
46.22
+266.01%
12.63
Net PPE Purchase And Sale
-0.11
+8.26%
-0.12
+90.76%
-1.31
-116.36%
-0.60
Purchase Of PPE
-0.11
+8.26%
-0.12
+90.76%
-1.31
-116.36%
-0.60
Capital Expenditure
-0.11
+99.69%
-35.93
-2644.92%
-1.31
-116.36%
-0.60
Net Investment Purchase And Sale
49.31
+245.72%
-33.84
-171.19%
47.53
+259.17%
13.23
Purchase Of Investment
-39.73
+66.89%
-119.98
+11.57%
-135.68
+17.65%
-164.75
Sale Of Investment
89.04
+3.36%
86.14
-52.98%
183.20
+2.93%
177.99
Net Business Purchase And Sale
-0.83
0.00
—
—
Purchase Of Business
-0.83
0.00
—
—
Gain Loss On Sale Of Business
—
—
—
—
Net Intangibles Purchase And Sale
0.00
+100.00%
-35.81
0.00
—
Purchase Of Intangibles
0.00
+100.00%
-35.81
0.00
—
Financing Cash Flow
-5.86
-107.86%
74.54
+179.10%
26.71
-63.35%
72.87
Cash Flow From Continuing Financing Activities
-5.86
-107.86%
74.54
+179.10%
26.71
-63.35%
72.87
Net Issuance Payments Of Debt
—
—
0.00
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
0.00
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
0.00
-100.00%
74.91
+180.43%
26.71
-63.28%
72.74
Proceeds From Stock Option Exercised
0.00
-100.00%
0.03
-65.96%
0.09
-40.13%
0.16
Net Other Financing Charges
-5.86
-1333.25%
-0.41
-300.98%
-0.10
-200.00%
-0.03
Changes In Cash
-4.61
+69.89%
-15.31
-183.53%
-5.40
-130.11%
17.93
Beginning Cash Position
24.57
-38.39%
39.88
-11.92%
45.28
+65.55%
27.35
End Cash Position
19.96
-18.76%
24.57
-38.39%
39.88
-11.92%
45.28
Free Cash Flow
-47.22
+15.68%
-56.01
+29.67%
-79.63
-16.81%
-68.17
Common Stock Issuance
0.00
-100.00%
74.91
+180.43%
26.71
-63.28%
72.74
Issuance Of Capital Stock
0.00
-100.00%
74.91
+180.43%
26.71
-63.28%
72.74
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category